Channel Therapeutics Corporation (CHRO)
NYSEAMERICAN: CHRO · Real-Time Price · USD
0.643
-0.010 (-1.45%)
At close: Dec 20, 2024, 4:00 PM
0.650
+0.007 (1.01%)
After-hours: Dec 20, 2024, 6:04 PM EST
Channel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
3.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 199.93K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCHRO News
- 1 day ago - Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine - GlobeNewsWire
- 3 days ago - Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model - GlobeNewsWire
- 4 weeks ago - Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates - GlobeNewsWire
- 7 weeks ago - Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - GlobeNewsWire
- 2 months ago - Chromocell Announces Amendment to Stock Repurchase Plan - GlobeNewsWire
- 3 months ago - Chromocell to Participate in Life Sciences Investor Forum September 19th - GlobeNewsWire
- 4 months ago - Chromocell Announces Stock Repurchase Plan - GlobeNewsWire
- 5 months ago - Chromocell to Participate in the Virtual Investor Lunch Break Series - GlobeNewsWire